MRFF disbursements

- Over $2 billion available over first six years (>2016-17)
- **2016-17** - $65.9m = 8 programs
- **2017-18** - $1,651.7m = 11 new programs + 4 extensions
  - long term investments – between four and five years
  - foundational programs – clinical trials, fellowships
  - cluster of ‘valley one’ support program to prime pipeline
  - brave missions of various sizes
  - preventive and health services improvement focus
  - introduction of commissioned research

**THEMES:** Patients, Researchers, Missions and Translation
Industry Growth Plan

- **Genomics Health Futures Mission** ($500m/10 years)
- **Frontier Research** ($240m/5 years) transformative health focussed research, two stages ‘THE PITCH’ EOI $1m x 1 year = 20 competing for ‘THE INVESTMENT’ $10-$20m pa > 5 years
- **BioMedTech Horizons** ($40m/4 years, extension) - bridge to commercialisation
- **Biomedical Translation Bridge** ($22.3m/4 years) innovative early ideas
- **Targeted Translation Research Accelerator** ($125m/9 years >2019-20)
- **Industry Researcher Exchange** ($32m/4 years) - joint appointment fellowships
- **Clinical Trials Activity** ($206m/5 years, extension)
- **International Clinical Trial Collaboration** ($42m/5 years)

- **Australian Medical Research Advisory Board** ($20m/4 years)
- **AIHW - Increased data linkage and release** ($30m/4 years ongoing)
- **Clinical Trials National Front Door** (preliminary work to develop concept)
Genomic Health Futures Mission (500m /10 years)

**VISION:** Australians living longer and better through access to genomic knowledge and technology

- **FLAGSHIPS** – rare cancers, rare diseases and complex conditions
- **CLINICAL TRIALS** – pre-clinical, functional genomics and targeted and adaptive clinical trials
- **WORKFORCE AND RESEARCHERS** – creation of new highly skilled workforce and new career pathways
- **COMMERCIALISATION** – pharmacological genomics and new to world industries
- **ETHICS, LEGAL AND SOCIAL** – community dialogue that gains technology appreciation and value
- **DATA AND ANALYTICS** – secure storage, access, analysis and sharing with benefit to patients
Groundwork on genomics …

A Summary: National Health Genomics Policy Framework

<table>
<thead>
<tr>
<th>Vision</th>
<th>Helping people live longer and better through appropriate access to genomic knowledge and technology to prevent, diagnose, treat and monitor disease.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mission</td>
<td>To integrate the health benefits of genomic knowledge and technology into the Australian health care system in an efficient, effective, ethical and equitable way to improve individual and population health.</td>
</tr>
<tr>
<td>Enablers of success</td>
<td>Collaboration, governance and workforce, stakeholders engagement, National and international partnerships.</td>
</tr>
</tbody>
</table>

Person-centred approach

- Delivering high-quality care by people through a person-centred approach to integrating genomic information and health care.

Workforce

- Building a skilled workforce that is numerate in genomics.

Financing

- Ensuring sustainable and strategic investment in cost-effective genomics.

Services

- Ensuring quality, safety and cultural sensitivity of genomics in health care.

Data

- Responsible collection, storage, use and management of genomic data.

Principles

- The application of genomic knowledge is ethically, legally and socially responsible and community trust is promoted.

- Access and equity are promoted for vulnerable populations.

- The application of genomic knowledge to health care is supported and informed by evidence and research.

NATIONAL POLICY COHESION

STRATEGIC PRIORITIES:

1. person-centred approach
2. workforce
3. financing
4. services
5. Data

PRINCIPLES:

- The application of genomic knowledge is ethically, legally and socially responsible and community trust is promoted.
- Access and equity are promoted for vulnerable populations.
- The application of genomic knowledge to health care is supported and informed by evidence and research.
Precision medicine has a broad remit – genomics and other omics, epigenetics, gene editing technologies and development of targeted therapies for an individual’s disease profile

**CATALYSTS:**
1. advances in sequencing technology
2. new treatment, prediction and prevision means
3. collect and codify clinical and research data

Advances will reshape healthcare, invigorate the biotechnology sector and stimulate new fields of research
Imperative 5 – Culture and ambition: Enhance the national culture of innovation by launching ambitious National Missions

Strategic opportunity 5.1

A Genomics and Precision Medicine National Mission will be an ideal first mission, delivering health and innovation benefits for all Australians
Ministerial priorities:

- **McKenzie’s Mission** - $20m large scale research pilot on reproductive carrier screening to generate evidence for system integration

- **ProCan** - $20m cancer proteomics

- **Australian Genomics Cancer Medicine Program** - $50m (non-MRFF) to be matched by leveraged funding from participating centres, industry and philanthropy, to establish eight centres of excellence Australia-wide to deliver genomics-based clinical trials to around 5,000 Australians affected by rare, less common and early onset cancers
Mission Steering Committee

- Time limited – convened for the explicit purpose of determining an operational plan for the Mission to be considered by Government at the end of the year

- This PLAN will among other things:
  - outline the vision and scope to drive patient outcomes and technology application
  - define the rationale, objectives, operating principles and policy context
  - consider best governance solutions – National Genomics Health Policy Framework
  - provide a decision making framework and scientific peer review process for ensuring only the best research in funded – MRFF Funding Principles
  - determine the program logic to support investment decisions, program design and implementation
  - provide a structured business case to support data and analytics capacity
  - establish a monitoring, evaluation and risk framework
  - provide a communication and community engagement framework
  - determine specific strategies for addressing the social, ethical and legal issues
Welcome considerations from today …

- What is a reasonable Mission scope – genomics and/or beyond?
- What does success look like in 10 years time?
- What is achievable in 10 years with $500 million?
- How can we ‘scale up’ rather than reinvent?
- How can we shift from ‘cottage industry’ to mainstream application?
- What does it mean for genomics to be business as usual?
- What capabilities are needed and how are they best organised?
- Are there any ‘must have’ features in the Mission architecture to ensure success?
- What are the opportunities for leverage and growth?
- How can the ethical, legal and social issues be addressed?
More information:
MRFF@health.gov.au

2018-19 Budget Factsheets
Life saving and job creating medical research
www.health.gov.au

Interested in accessing MRFF grants?
Register with GRANTCONNECT (www.grants.gov.au)
• enables notification of new grants in areas of interest

Thank you